# OnCo record next-generation-adc-payloads (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/next-generation-adc-payloads/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "next-generation-adc-payloads" ;
  schema:name "Next-generation antibody-conjugate payloads"@en ;
  schema:alternateName "non-TOP1 payloads"@en, "novel ADC payload mechanisms"@en, "ADC payload diversification"@en ;
  schema:description "Antibodies can carry drugs that block gene reading, remove proteins, interrupt cell signals or activate immune cells. Each approach needs its own evidence that the drug reaches its target and helps people safely."@en ;
  schema:url <https://onco.cc/terms/next-generation-adc-payloads/> ;
  schema:dateModified "2026-11-09"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/33722857/>, <https://pubmed.ncbi.nlm.nih.gov/33722858/>, <https://pubmed.ncbi.nlm.nih.gov/35511740/>, <https://doi.org/10.1038/s41467-021-23793-7>, <https://doi.org/10.1038/s41591-026-04518-z> ;
  onco:related <https://onco.cc/terms/af-hpa/>, <https://onco.cc/terms/dm21-c-maytansinoid-system/>, <https://onco.cc/terms/transcription-inhibitor-payloads/>, <https://onco.cc/terms/amanitin-payloads/>, <https://onco.cc/terms/triptolide-payloads/>, <https://onco.cc/terms/spliceosome-inhibitor-payloads/>, <https://onco.cc/terms/cdk-inhibitor-payloads/>, <https://onco.cc/terms/ddr-inhibitor-payloads/>, <https://onco.cc/terms/atr-inhibitor-payloads/>, <https://onco.cc/terms/nampt-inhibitor-payloads/>, <https://onco.cc/terms/bcl-xl-inhibitor-payloads/>, <https://onco.cc/terms/mcl1-inhibitor-payloads/>, <https://onco.cc/terms/hdac-inhibitor-payloads/>, <https://onco.cc/terms/gspt1-degrader-payloads/>, <https://onco.cc/terms/brd4-degrader-payloads/>, <https://onco.cc/terms/kif11-degrader-payloads/>, <https://onco.cc/terms/ksp-inhibitor-payloads/>, <https://onco.cc/terms/sting-agonist-payloads/>, <https://onco.cc/terms/tlr-agonist-payloads/>, <https://onco.cc/terms/gq11-inhibitor-payloads/>, <https://onco.cc/terms/pi3k-pikk-inhibitor-payloads/>, <https://onco.cc/terms/tubulysin-payloads/>, <https://onco.cc/terms/hemiasterlin-payloads/>, <https://onco.cc/terms/eribulin-payload/>, <https://onco.cc/terms/cryptophycin-payloads/>, <https://onco.cc/terms/anthracycline-payloads/>, <https://onco.cc/terms/ign-payloads/>, <https://onco.cc/terms/pdd-payloads/>, <https://onco.cc/terms/protein-alkylator-payloads/>, <https://onco.cc/terms/proteasome-inhibitor-payloads/>, <https://onco.cc/terms/ferroptosis-conjugate-payloads/>, <https://onco.cc/terms/protein-toxin-payloads/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/dual-payload-adc/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/immune-stimulating-adc/>, <https://onco.cc/technologies/radioimmunotherapy/>, <https://onco.cc/technologies/antibody-oligonucleotide-conjugates/>, <https://onco.cc/technologies/photoimmunotherapy/> ;
  onco:terms <https://onco.cc/terms/payload/> .
